Yap1 Activation Enables Bypass of Oncogenic Kras Addiction in Pancreatic Cancer

Kapoor, Avnish, Yao, Wantong, Ying, Haoqiang, Hua, Sujun, Liewen, Alison, Wang, Qiuyun, Zhong, Yi, Wu, Chang-Jiun +22 more·2014·Cell
DOI 10.1016/j.cell.2014.06.003

Cited by (717)

Items 601–700 of 717

  1. Therapeutic Targeting of RAS Mutant Cancers
    Edward C. Stites, Kendra V. Paskvan, Shumei Kato · 2022 · Cambridge University Press eBooks
  2. An integrated model for predicting KRAS dependency
    2023
  3. Exploring the role of YAP1 and TAZ in pancreatic acinar cells and the therapeutic potential of VT-104 in pancreatic inflammation
    Kevin M Lopez, Janice Deng, Yi Xu, Francis E. Sharkey, Pei Wang, Jun Liu · 2024 · Journal of Pancreatology
  4. Discovery and In Vivo Evaluation of Aryl Ether YAP1/TEAD Inhibitors for the Treatment of Hippo-Driven Malignancies
    Brandon Vara, Jongwon Lim, Casey J. Moure, Sebastian E. Schneider, Charles See Yeung, Cayetana Zárate, Abdelghani Achab, Mangeng M. Cheng, Ronald M. Kim, R. Foti et al. · 2026 · Journal of Medicinal Chemistry
  5. Ras Homolog Family Member V Promotes Pancreatic Ductal Adenocarcinoma Progression
    Shang Wu, Jia Feng, Ting Wang, Kyler Hwa, Selina Kao, Ying Xiao, Dongfang Yang, Xinjian Li, Zebang Li, Ryan Liu et al. · 2026 · American Journal Of Pathology
  6. YAP1 signaling and cancer: molecular pathways reveal novel targeting opportunities
    Jialin Wu, Bonan Chen, Fuda Xie, Jiahui Hu, Mingyu Liang, Yang Lyu, Peiyao Yu, Tiejun Feng, Ruoxi Tian, Wei Kang · 2026 · Expert Opinion on Therapeutic Targets
  7. Cancer cell development, migratory response, and the role of the tumor microenvironment in invasion and metastasis
    Inés M. Antón, Francisco G. Wandosell, Miguel Vicente‐Manzanares · 2022 · Elsevier eBooks
  8. A special subtype: Revealing the potential intervention and great value of KRAS wildtype pancreatic cancer
    Zhihang Xu, Wenquan Wang, Liang Liu, Wenhui Lou · 2022 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
  9. Targeting KRAS and SHP2 signaling pathways for immunomodulation and improving treatment outcomes in solid tumors
    Priyanka Sahu, Ankita Mitra, Anirban Ganguly · 2024 · International review of cytology
  10. Rac1 GTPase Regulates the βTrCP-Mediated Proteolysis of YAP Independently of the LATS1/2 Kinases
    Chitra Palanivel, Tabbatha N. Somers, Bailey M. Gabler, Yuanhong Chen, Yongji Zeng, Jesse L. Cox, Parthasarathy Seshacharyulu, Jixin Dong, Ying Yan, Surinder K. Batra et al. · 2024 · Cancers
  11. Road Map to Defeat Pancreatic Cancer
    Lesley Paige Ferguson, David Arthur Tuveson · 2025 · Annual Review of Cancer Biology
  12. Tension and Transformation in Pancreas Cancer: Can Phenotype Break Free from the Chrysalis of Genotype?
    Christopher C. DuFort, Sunil R. Hingorani · 2016 · Cancer Cell
  13. Emerging Therapeutic Targets in Pancreatic Adenocarcinoma
    Jennifer Hsing Choe, James L. Abbruzzese · 2016 · Springer eBooks
  14. Blockage of glioma cell survival by truncated TEAD-binding domain of YAP
    Wei Zhao, Qiu‐Feng Dong, Liwen Li, Zhifeng Yan, Junli Huo, Xiao-yan Chen, Xin Yang, Peng-Qi Li, Zhou Fei, Hai-ning Zhen · 2021 · Journal of Cancer Research and Clinical Oncology
  15. Emerging Therapeutic Targets in Pancreatic Adenocarcinoma
    Jennifer Hsing Choe, James L. Abbruzzese · 2018 · Springer eBooks
  16. Current Model Systems for Investigating Epithelioid Haemangioendothelioma
    Emily Neil, Valérie Kouskoff · 2023 · Cancers
  17. Selective targeting of KRAS-driven lung tumorigenesis via unresolved ER stress
    Iwao Shimomura, Naoaki Watanabe, Tomofumi Yamamoto, Minami Kumazaki, Yuji Tada, Koichiro Tatsumi, Takahiro Ochiya, Yusuke Yamamoto · 2021 · JCI Insight
  18. Viral manipulation of mechanoresponsive signaling disassembles processing bodies
    Elizabeth L. Castle, Carolyn-Ann Robinson, Pauline Douglas, Kristina D. Rinker, Jennifer A. Corcoran · 2020 · bioRxiv (Cold Spring Harbor Laboratory)
  19. Multiplexed Quantitative Screens of Single Cell Shape and YAP/TAZ Localisation Identify DOCK5 as a Coincident Detector of Polarity and Adhesion During Migration
    Patricia Pascual Vargas, Mar Arias-García, Theodoros I. Roumeliotis, Jyoti Sharma Choudhary, Chris Bakal · 2020 · bioRxiv (Cold Spring Harbor Laboratory)
  20. Targeting the Hippo pathway in cancers via ubiquitination dependent TEAD degradation
    Trang H. Pham, Kanika Bajaj Pahuja, Thijs J. Hagenbeek, Jason Zbieg, Cameron L. Noland, Victoria C. Pham, Xiaosai Yao, Christopher M. Rose, Kristen C. Browder, Ho-June Lee et al. · 2024 · eLife
  21. Tumor Cell Spatial Organization Directs EGFR/RAS/RAF Pathway Primary Therapy Resistance through YAP Signaling
    Rachel M. Nakagawa, Andrew R. Beardsley, Sophia Durney, Mary-Kate Hayward, Vishvak Subramanyam, Nathaniel P. Meyer, Harrison Wismer, Hani Goodarzi, Valerie Marie Weaver, Daniel Van de Mark et al. · 2025 · eLife
  22. Transposon mediated functional genomic screening for BRAF inhibitor resistance reveals convergent Hippo and MAPK pathway activation events
    Li Chen, Iulian Pruteanu-Malinici, Anahita Dastur, Xunqin Yin, Dennie Tompers Frederick, Ruslan I. Sadreyev, Cyril H. Benes · 2025 · Scientific Reports
  23. PR55α subunit of protein phosphatase 2A supports KRASG12D-driven tumorigenesis that requires YAP activation
    Christopher B Jenkins, Alison L. Camero, Brendan T Graff, Lepakshe S. V. Madduri, Kelly A. O’Connell, Ashley L. Hein, Lynette M. Smith, Charles A. Enke, Jixin Dong, Michael Anthony Hollingsworth et al. · 2025 · Oncogene
  24. Roles of TEAD Transcription Factors and their Coactivators in the Progression and Metastasis of Cancers
    Xiao Fan Li, Ning Zhang, Peng-Quan Li, Hai-Qing Chu, Dong Hui Zhao, Wei Dong Qin, Shouping Gong, Hui‐Ling Cao · 2025 · Recent Patents on Anti-Cancer Drug Discovery
  25. TIMP-1 Modulation Correlates with KRAS Dependency and EMT Induction in NSCLC
    Ilamathi M-Thirusenthilarasan, Pankaj Kumar Ahluwalia, Nithyananda Thorenoor, Sampa Ghoshal-Gupta, Byung Rho Lee, Bilal Karim Siddiqui, Ravindra B Kolhe, Amyn M. Rojiani, Mumtaz V. Rojiani · 2025 · Cells
  26. Pancreatic cancer: emerging small molecule pharmacotherapies
    Barbara Pokora, Kacper Pokora, Jakub Fichna · 2026 · Expert Opinion on Pharmacotherapy
  27. The emerging role of the Hippo signaling pathway in interorgan crosstalk
    Gahyeon Song, Chaerin Lee, E. Jho · 2026 · The FEBS Journal
  28. KRAS Mutations Reprogram RNA m6A Modifications to Drive CD73-Dependent Immune Evasion in Colorectal Cancer
    Seungjae Shin, Seung-Pyo Hong, Seoho Lee, Yeonseo Jang, Jisoo Yang, Jaeik Oh, Dongjun Jang, Soo-Jin Lee, Jiwon Kim, Sang Eun Lee et al. · 2026 · Cancer Research
  29. Biofabrication and artificial intelligence strategies for investigating solid- and fluid-pressure mechanobiology in pancreatic ductal adenocarcinoma
    Yahui Ding, Peiyuan Zhao, Jin Yan, Yan Li, Zifei Wang, Ye Lu, Yichen Zhang, Hongzhuan Chen, Weidong Zhang, Xin Luan et al. · 2026 · Cancer and Metastasis Reviews
  30. Developmental and MAPK-responsive transcription factors regulate distinct malignant cell states and associated genetic dependencies in pancreatic cancer
    Pasquale Laise, Mikko Turunen, Álvaro Curiel‐García, Lorenzo Tomassoni, H. Carlo Maurer, Ela Elyada, Bernhard Schmierer, Jeremy Worley, Jordan S. Kesner, Xiangtian Tan et al. · 2026 · Nature Genetics
  31. KRAS is required for plexiform neurofibroma formation and represents a targetable vulnerability in established tumors
    Liang Hu, Niousha Ahmari, Abby Schaeper, Jay Pundavela, Mi‐Ok Kim, Eva Dombi, Jianqiang Wu, Julia Brunmair, Özlem Yüce Petronczki, Nancy Ratner · 2026 · Science Advances
  32. Lineage identity governs oncogene dependence in mouse NSCLC models of KRAS inhibitor resistance
    Nicolas Mathey‐Andrews, Carrie L. Rodriguez, Bing Shui, Agata L. Patriotis, William M. Rideout, Victor Z. Chen, Ileana Murazzi, Phaedra Ghazi, Milton R. Cornwall-Brady, Manyuan Liu et al. · 2026 · Nature Genetics
  33. One way to rule them all: G2/M gene regulation by oncogenic YAP1 and B-MYB
    Grit Weinstock, Stefan Gaubatz · 2019 · Molecular & Cellular Oncology
  34. Cell Signaling and Translational Developmental Therapeutics
    Paul Dent · 2020 · Elsevier eBooks
  35. Cell Signaling and Translational Developmental Therapeutics
    Paul Dent · 2021 · Elsevier eBooks
  36. YAP/TAZ-mediated resistance to EGFR inhibitors
    Hirohito Yamaguchi, Ghina M. Taouk · 2023 · Elsevier eBooks
  37. Molecular Genetic Profiling of Adolescent Glassy Cell Carcinoma of the Cervix Reveals Targetable EGFR Amplification with Potential Therapeutic Implications
    Troy A. McEachron, Leonard S. Sender, Keri B. Zabokrtsky, Brian Kaltenecker, W. Nathan Holmes, Irene Cherni, Zarko Manojlovic, Shu‐Yuan Liao, David Wesley Craig, John David Carpten et al. · 2016 · Journal of Adolescent and Young Adult Oncology
  38. Evolving trends in pancreatic cancer therapeutic development
    Imani Bijou, Jin Wang · 2019 · Annals of Pancreatic Cancer
  39. Neratinib as a Potential Therapeutic for Mutant RAS and Osimertinib-Resistant Tumours
    Paul Dent, Laurence A. Booth, Andrew Stewart Poklepovic, John F. Hancock · 2022 · European Medical Journal
  40. Investigation of KRAS Dependency Bypass and Functional Characterization of All Possible KRAS Missense Variants
    Seav Huong Ly · 2018 · Digital Access to Scholarship at Harvard (DASH) (Harvard University)
  41. YAP/TAZ enhance P-body formation to promote tumorigenesis
    Xia Shen, Xiang Peng, Yuegui Guo, Zhujiang Dai, Long Cui, Wei Yu, Yun Liu, Chen‐Ying Liu · 2023 · bioRxiv (Cold Spring Harbor Laboratory)
  42. Targeting the Hippo pathway in cancers via ubiquitination dependent TEAD degradation
    Trang H. Pham, Kanika Bajaj Pahuja, Thijs J. Hagenbeek, Jason Zbieg, Cameron L. Noland, Victoria C. Pham, Xiaosai Yao, Christopher M. Rose, Kristen C. Browder, Ho-June Lee et al. · 2024 · eLife
  43. Tumor Cell Spatial Organization Directs EGFR/RAS/RAF Pathway Primary Therapy Resistance through YAP Signaling
    Rachel M. Nakagawa, Andrew R. Beardsley, Sophia Durney, Mary-Kate Hayward, Vishvak Subramanyam, Nathaniel P. Meyer, Harrison Wismer, Hani Goodarzi, Valerie Marie Weaver, Daniel Van de Mark et al. · 2025 · eLife
  44. The role of PAK4 in pancreatic cancer
    Helen A. King · 2014
  45. Strategies to Target Pancreatic Cancer
    Geou‐Yarh Liou, Peter Störz · 2016 · Springer eBooks
  46. Cross Talk Between Snail and Mutant K-Ras Contributes to Pancreatic Cancer Progression
    Christina R. Chow, Kazumi Ebine, Holly Z. Hattaway, Krishan Kumar, Hidayatullah G. Munshi · 2016 · Elsevier eBooks
  47. Engineering solutions for cancer
    Peter D. Weinberg, Armando E. del Río Hernández, Robert Eldon Brown · 2017 · Convergent Science Physical Oncology
  48. Establishment in Culture of Expanded Potential Stem Cells
    Jian Ping Yang, David John Ryan, Wei Wang, Jason Cheuk-Ho Tsang, Guocheng Lan, Hideki Masaki, Xuefei Gao, Liliana Antunes, Yong Yu, Zhexin Zhu et al. · 2017 · bioRxiv (Cold Spring Harbor Laboratory)
  49. Specificity protein 1 induces the expression of angiomotin in response to IL-6/STAT3 activation to mediate YAP-dependent growth of breast cancer cells
    Lauren R. Bringman · 2016 · IUScholarWorks (Indiana University)
  50. Understanding and Targeting Tumor Microenvironment in Prostate Cancer to Inhibit Tumor Progression and Castration Resistance
    Xin Lü · 2015
  51. [Should heart surgery and thromboendarterectomy of the carotid artery be done simultaneously?].
    Jan T. Christenson, J Maurice, François Simonet, Vladimir Velebit, Martin Schmuziger · 1996 · PubMed
  52. The Role of Hippo Pathway in Mitosis and Cancer
    Xingcheng Chen · 2018 · DigitalCommons@UNMC
  53. Gnas R201C Induces Murine Pancreatic Cystic Neoplasms through Suppression of YAP1 Signaling and Transcriptional Reprogramming
    Noboru Ideno, Hiroshi Yamaguchi, Bidyut Ghosh, Sonal Gupta, Takashi Okumura, Catherine G. Fisher, Laura DeLong Wood, Aatur Dilip Singhi, Masafumi Nakamura, Jorge Silvio Gutkind et al. · 2018 · bioRxiv (Cold Spring Harbor Laboratory)
  54. Identification and Characterization of Novel Upstream Regulators of the Hippo Signalling Pathway
    Emad Heidaryarash · 2018 · TSpace (University of Toronto)
  55. Elucidating the Mechanisms of Apoptosis Induced by a Novel Geranylgeranyl Diphosphate Synthase Inhibitor in T-cell Acute Lymphoblastic Leukemia
    Sherry S. Agabiti · 2018 · OpenCommons at University of Connecticut (University of Connecticut)
  56. The mechanism and efficacy of targeting YAP-TEAD in colorectal cancer
    박지수 · 2018 · YUHSpace (Yonsei University Medical Library)
  57. Chemo-prevention and interception of obesity-promoted pancreatic ductal adenocarcinoma
    Hui-Hua Chang, Guido Eibl · 2019 · Elsevier eBooks
  58. Identification and functional characterisation of gene fusions in human cancer cell lines
    Elisabeth Daisy Chen · 2018 · Apollo (University of Cambridge)
  59. Regulation of the kRAS Promoter in Pancreatic Cancer by Proteins and Small Molecules
    Harshul Batra · 2017 · ProQuest Demo Repository
  60. Investigating Molecular Mechanisms of Drug Resistance in a 3D Cell Culture Model of Pancreatic Cancer
    Arthur Brannon · 2017 · Deep Blue (University of Michigan)
  61. Molecular mechanisms of YAP signalling in the context of cancer
    Bailu Xie · 2019
  62. UDP-glucose pyrophosphorylase 2, a regulator of glycosylation and glycogen, is essential for pancreatic cancer growth
    Andrew L. Wolfe, Qingwen Zhou, Eneda Toska, Jacqueline Galeas, Angel A. Ku, Richard P. Koche, Sourav Bandyopadhyay, Maurizio Scaltriti, Carlito B. Lebrilla, Frank P. McCormick et al. · 2020 · bioRxiv (Cold Spring Harbor Laboratory)
  63. YAP1 protein expression has variant prognostic significance in SCLC stratified by histological subtypes
    Xin Wang, Yiying Guo, Li Liu, Jiacong Wei, Jinyao Zhang, Tongji Xie, Jiyan Dong, Junling Li, Puyuan Xing, Lin Yang · 2021 · Research Square
  64. Ras and Ras Signaling as a Therapeutic Target in Cancer
    Bailee H. Sliker, Paul M. Campbell · 2021 · Elsevier eBooks
  65. SPINT2 Suppresses Hippo Effector YAP and Limits Cellular Tolerance for Aneuploidy
    Huadi Zhang · 2017 · Digital Access to Scholarship at Harvard (DASH) (Harvard University)
  66. Capicua Suppresses YAP1 To Limit Tumorigenesis and Maintain Drug Sensitivity in Human Cancer
    Ji Won Kim, Cuyler Luck, Wei Wu, Rovingaile Kriska Ponce, Yone Kawe Lin, Nehal Gupta, Ross A. Okimoto · 2021 · SSRN Electronic Journal
  67. Methyl Epigenetic Mechanisms in the Freeze-Tolerance Response of Rana Sylvatica Nervous Tissue
    Tighe Bloskie · 2021
  68. Patent Highlights
    Hermann AM Mucke · 2014 · Pharmaceutical Patent Analyst
  69. YAP1 protein expression has variant prognostic significance in SCLC stratified by histological subtypes
    Xin Wang, Yiying Guo, Li Liu, Jiacong Wei, Jinyao Zhang, Tongji Xie, Jiyan Dong, Junling Li, Puyuan Xing, Lin Yang · 2021 · Research Square
  70. Faculty Opinions recommendation of Reprogramming normal cells into tumour precursors requires ECM stiffness and oncogene-mediated changes of cell mechanical properties.
    Beatriz Sosa‐Pineda, Angelica S Martínez-Ramírez · 2020 · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
  71. YAP1 Protein Expression Has Variant Prognostic Significance in SCLC Stratified by Histological Subtypes
    Xin Wang, Yiying Guo, Li Liu, Jiacong Wei, Jinyao Zhang, Tongji Xie, Jiyan Dong, Junling Li, Puyuan Xing, Lin Yang · 2021 · Research Square
  72. Tuneable 3D biocompatible scaffolds for biological and biophysical solid-tumour microenvironment studies; applications in Ovarian Cancer
    Francesca Paradiso · 2022
  73. TEAD is required for DNA repair independent of its transcriptional function
    Philamer C. Calses, Victoria C. Pham, Erik Verschueren, Sietske T. Bakker, Benjamin Haley, Chad Liu, Matthew T. Chang, Noelyn M. Kljavin, Trent B. Hinkle, Jianing Zou et al. · 2022 · Research Square
  74. Discovery of a ‘Grail-Shaped’ Drug: Ne-ratinib and the Downregulation of Mutant RAS
    Paul Dent, Andrew Stewart Poklepovic, Laurence A. Booth · 2019 · EMJ Oncology
  75. Data from Opposite Effects of Src Family Kinases on YAP and ERK Activation in Pancreatic Cancer Cells: Implications for Targeted Therapy
    James W. Sinnett‐Smith, Tarique Anwar, Elaine F. Reed, Yaroslav Teper, Guido Eibl, Enrique Rozengurt · 2023
  76. Data from Machine-Learning and Chemicogenomics Approach Defines and Predicts Cross-Talk of Hippo and MAPK Pathways
    Trang H. Pham, Thijs J. Hagenbeek, Ho‐June Lee, Jason Li, Christopher M. Rose, Eva Lin, Mamie Yu, Scott E. Martin, Robert Piskol, Jennifer Arca Lacap et al. · 2023
  77. Supplementary Methods, Figure Legends, Figures S1 - S7 from Targeting YAP-Dependent MDSC Infiltration Impairs Tumor Progression
    Guocan Wang, Xin Lu, Prasenjit Dey, Pingna Deng, Chia-Chin Wu, Shan Jiang, Zhuangna Fang, Kun Zhao, Ramakrishna Konaparthi, Sujun Hua et al. · 2023
  78. Supplementary Figure S10 from Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC
    Marcelo Vailati Negrao, Haniel Alves Araújo, Giuseppe Lamberti, Alissa Jamie Cooper, Neal S. Akhave, Teng Zhou, Lukas Delasos, James Kevin Hicks, Mihaela D. Aldea, Gabriele Minuti et al. · 2023
  79. Supplementary Figure S10 from Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC
    Marcelo Vailati Negrao, Haniel Alves Araújo, Giuseppe Lamberti, Alissa Jamie Cooper, Neal S. Akhave, Teng Zhou, Lukas Delasos, James Kevin Hicks, Mihaela D. Aldea, Gabriele Minuti et al. · 2023
  80. Supplementary Figure S10 from Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC
    Marcelo Vailati Negrao, Haniel Alves Araújo, Giuseppe Lamberti, Alissa Jamie Cooper, Neal S. Akhave, Teng Zhou, Lukas Delasos, James Kevin Hicks, Mihaela D. Aldea, Gabriele Minuti et al. · 2023
  81. Supplementary Figure S10 from Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC
    Marcelo Vailati Negrao, Haniel Alves Araújo, Giuseppe Lamberti, Alissa Jamie Cooper, Neal S. Akhave, Teng Zhou, Lukas Delasos, James Kevin Hicks, Mihaela D. Aldea, Gabriele Minuti et al. · 2023
  82. YAP/TAZ enhance P-body formation to promote tumorigenesis
    Xia Shen, Xiang Peng, Yuegui Guo, Zhujiang Dai, Long Cui, Wei Yu, Yun Liu, Chen‐Ying Liu · 2023 · eLife
  83. Targeting the Hippo pathway in cancers via ubiquitination dependent TEAD degradation
    Trang H. Pham, Kanika Bajaj Pahuja, Thijs J. Hagenbeek, Jason Zbieg, Cameron L. Noland, Victoria C. Pham, Xiaosai Yao, Christopher M. Rose, Kristen C. Browder, Ho-June Lee et al. · 2023 · bioRxiv (Cold Spring Harbor Laboratory)
  84. Data from CRISPR Screening Identifies Mechanisms of Resistance to KRASG12C and SHP2 Inhibitor Combinations in Non–Small Cell Lung Cancer
    Anirudh Prahallad, Andreas Weiss, Hans Voshol, Gráinne Kerr, Kathleen Sprouffske, Tina L. Yuan, David A. Ruddy, Morgane Meistertzheim, Malika Kazic-Legueux, Tina Kottarathil et al. · 2023
  85. Data from CRISPR Screening Identifies Mechanisms of Resistance to KRASG12C and SHP2 Inhibitor Combinations in Non–Small Cell Lung Cancer
    Anirudh Prahallad, Andreas Weiss, Hans Voshol, Gráinne Kerr, Kathleen Sprouffske, Tina L. Yuan, David A. Ruddy, Morgane Meistertzheim, Malika Kazic-Legueux, Tina Kottarathil et al. · 2023
  86. YAP/TAZ enhance P-body formation to promote tumorigenesis
    Xia Shen, Xiang Peng, Yuegui Guo, Zhujiang Dai, Long Cui, Wei Yu, Yun Liu, Chen‐Ying Liu · 2024 · eLife
  87. Additional file 5 of Promoter hypermethylation and comprehensive regulation of ncRNA lead to the down-regulation of ZNF880, providing a new insight for the therapeutics and research of colorectal cancer
    Xiangqian Dong, Yinghui Zhang, Yang Sun, Qiong Nan, Maojuan Li, Lanqing Ma, Lei Zhang, Juan Luo, Yating Qi, Yinglei Miao · 2023 · Figshare
  88. Relationship of pancreatitis to pancreatic cancer: from population-based observations to preclinical and mechanistic insights
    Xiuli Zhang, Zhigao Chen, Xiong Hu Zhao, Jiachun Pan, Stephen Jacob Pandol, Wen Li · 2024 · Journal of Pancreatology
  89. Therapeutic targeting of Syndecan-1 axis overcomes acquired resistance to KRAS-targeted therapy in gastrointestinal cancers
    Mitsunobu Takeda, Madelaine Skolastika Theardy, Alexey V. Sorokin, Oluwadara Coker, Preeti Kanikarla Marie, Shuaitong Chen, Zecheng Yang, Phuoc Thi-My Nguyen, Yongkun Wei, Jun Yao et al. · 2024 · bioRxiv (Cold Spring Harbor Laboratory)
  90. Tumor Cell Spatial Organization Directs EGFR/RAS/RAF Pathway Primary Therapy Resistance through YAP Signaling
    Rachel Nakagawa, Andrew Beardsley, Sophia Durney, Mary-Kate Hayward, Vishvak Subramanyam, Nathaniel P. Meyer, Harrison Wismer, H. Goodarzi, V. Weaver, Daniel Van de Mark et al. · 2024 · bioRxiv
  91. KRAS-driven cancer models for in vivo pharmacology and drug discovery
    Seema Chugh, Lukas E. Dow, Mallika Singh, Andrew J. Aguirre · 2024 · Elsevier eBooks
  92. YAP signaling promotes resistance to MEK and AKT inhibition in NF1 -related MPNSTs
    Lauren E. McGee, Jamie L. Grit, Curt J. Essenburg, Sophia Agrusa, Elizabeth A. Tovar, Lisa Turner, Katelyn Becker, Jason Zbieg, Anwesha Dey, Jennifer E. Klomp et al. · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
  93. MED12 mutation induces RTK inhibitor resistance in NSCLC via MEK/ERK pathway activation by inflammatory cytokines
    Hyun-Min Ryu, Deokhoon Kim, Jun Yong Choi, Shinkyo Yoon, Ho‐Su Lee, Ji Eun Park, Eunjin Lee, Yunkyung Sung, Chang Hoon Lee, Eun-Young Lee et al. · 2025 · Cellular and Molecular Life Sciences
  94. Caenorhabditis elegans Uses Canonical and Non-canonical Hippo signaling
    Linh Huynh, Razan A. Fakieh, C’Brionne Hendrix, Reid Trenton Powell, David J. Reiner · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
  95. A YAP / TAZ – CDC6 Axis Initiates and Maintains Malignant Transformation
    David Nduru, Yudai Ohta, Akihiro Nita, Mayumi Niimura, Samson Ngurari, Toshiro Moroishi · 2025 · Cancer Science
  96. p53 and YAP/TAZ-TEAD activities determine metaplastic heterogeneity in pancreatic cancer
    Cole P Martin, Scott Bang, Joseph R. Gomes, William B. Sullivan, Yusha Liu, Matthew D. Smith, A. Cole Edwards, Channing J. Der, John P. Morris · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
  97. Additional file 1 of Overexpressed WDR3 induces the activation of Hippo pathway by interacting with GATA4 in pancreatic cancer
    Su, Wenjie, Zhu, Shikai, Chen, Kai, Yang, Hongji, Tian, Mingwu, Fu, Qiang, Shi, Ganggang, Feng, Shijian, Dianyun Ren, Jin, Xin et al. · 2021 · Figshare
  98. Additional file 4 of Promoter hypermethylation and comprehensive regulation of ncRNA lead to the down-regulation of ZNF880, providing a new insight for the therapeutics and research of colorectal cancer
    Xiangqian Dong, Zhang, Yinghui, Sun, Yang, Nan, Qiong, Li, Maojuan, Ma, Lanqing, Zhang, Lei, Luo, Juan, Yating Qi, Miao, Yinglei · 2023 · Figshare
  99. Additional file 3 of Promoter hypermethylation and comprehensive regulation of ncRNA lead to the down-regulation of ZNF880, providing a new insight for the therapeutics and research of colorectal cancer
    Xiangqian Dong, Zhang, Yinghui, Sun, Yang, Nan, Qiong, Li, Maojuan, Ma, Lanqing, Zhang, Lei, Luo, Juan, Yating Qi, Miao, Yinglei · 2023 · Figshare
  100. Additional file 1 of Promoter hypermethylation and comprehensive regulation of ncRNA lead to the down-regulation of ZNF880, providing a new insight for the therapeutics and research of colorectal cancer
    Xiangqian Dong, Zhang, Yinghui, Sun, Yang, Qiong Nan, Li, Maojuan, Ma, Lanqing, Zhang, Lei, Luo, Juan, Yating Qi, Miao, Yinglei · 2023 · Figshare